若生智能
Drug Database
PR

prednisolone farnesil (Farnezone / Farnesone / Farnerate)

✓ Approved

SK · NR3C1 · 小分子

什么是 prednisolone farnesil？

prednisolone farnesil 是一种小分子，由SK研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Farnezone, Farnesone, Farnerate
公司SK
药物类别小分子
分子靶点NR3C1
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, SK

作用机制

分子靶点

prednisolone farnesil 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone farnesil 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

相关研究文献

PubMedJFMS open reports2026-07-27

Suspected chronic eosinophilic leukemia in a cat treated with toceranib.

Mastrangelo Cristian C, Siegel Andrea A, Carruth Ariel A, Leibman Nicole N

A 16-year-old, spayed female domestic shorthair cat was referred to the Schwarzman Animal Medical Center for evaluation of chronic, progressive eosinophilia accompanied by vomiting and weight loss despite normal appetite. Blood smear evaluation revealed immature eosinophils with dysplastic features and occasional giant forms. Abdominal ultrasound identified small-intestinal thickening, a hepatopathy and splenomegaly. Screening for feline leukemia virus, feline immunodeficiency virus and heartworm infection were negative. Chronic eosinophilic leukemia was suspected, although hypereosinophilic syndrome could not be ruled out. At the time of referral, the cat was receiving prednisolone and chlorambucil for suspected small cell gastrointestinal lymphoma, but showed persistent clinical signs and progressive eosinophilia. Chlorambucil was discontinued and toceranib was initiated alongside prednisolone. No adverse effects attributable to toceranib were observed. A partial response, defined as resolution of clinical signs and a 30% reduction in circulating eosinophils, was observed on day 39. A subsequent progression-free survival interval of 4 weeks was achieved. Progressive disease developed on day 75, and given declining quality of life, euthanasia was thereby elected on day 89. This case report is the first to describe the use of toceranib to treat suspected chronic eosinophilic leukemia, a rare and poorly documented disease process in cats. This novel therapeutic approach is the first publication of a partial response and stable disease in the treatment of suspected chronic eosinophilic leukemia in a cat.

PMID 42504294
阅读全文 →
PubMedCureus2026-07-26

Transient Platelet Elevation Following Oseltamivir Administration in Pediatric Chronic Immune Thrombocytopenia.

Yamamoto Soh S, Furui Yu Y, Okura Eri E, Sakamoto Kenichi K et al.

Oseltamivir is widely used for influenza, but its effects on platelet counts in pediatric patients with chronic immune thrombocytopenia (cITP) remain unclear. We report three adolescents with cITP (four events) who showed transient platelet elevation after oseltamivir while receiving low-dose prednisolone and eltrombopag. Platelet counts increased nine to 14 days after oseltamivir initiation (median: 11.5 days), from a median of 9.1×104/μL to 26.7×104/μL; two events required eltrombopag dose reduction or temporary interruption. Platelet counts subsequently returned to approximately baseline within a median of 57 days, and no thrombosis, major bleeding, or other adverse events related to thrombocytosis were observed. Although causality cannot be established and influenza itself may contribute to platelet changes, clinicians should be aware that some children with cITP may develop transient platelet elevation after oseltamivir for influenza, which can complicate eltrombopag management and warrants planned platelet monitoring.

PMID 42502522
阅读全文 →
PubMedInternational medical case reports journal2026-07-26

Recurrent Pyoderma Gangrenosum with Initial Onset in Early Pregnancy: A PARACELSUS-Supported Clinical Diagnosis in a Resource-Limited Setting in South-Western Uganda.

Olwit Gerald G, Tumwesige Charles C, Nek Arthur Jonathan AJ, Chris-Uchendu Hans Chinomso HC et al.

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by rapidly progressive, painful cutaneous ulceration and remains a diagnosis of exclusion because no single laboratory or histopathological test is diagnostic. Establishing a clinically well-supported diagnosis is particularly challenging in resource-limited settings where histopathology and other advanced investigations are often unavailable, necessitating reliance on structured clinical assessment and validated diagnostic frameworks. A 26-year-old multiparous woman from South-Western Uganda presented with recurrent, progressively painful multifocal ulcerations involving both lower limbs and upper extremities. The initial episode developed during the first month of pregnancy as pruritic pustules that rapidly evolved into ulcerative lesions following minor trauma, with recurrence occurring two years later from a persistent non-healing ulcer. Comprehensive clinical evaluation found no evidence suggestive of inflammatory bowel disease (IBD) or other major associated systemic conditions, while wound cultures were sterile, supporting a non-infectious process. Because histopathology, gastrointestinal endoscopy, and other advanced investigations were unavailable, diagnosis relied on careful clinical assessment, systematic exclusion of important differential diagnoses, characteristic lesion morphology, pathergy, previous response to immunosuppressive therapy, and a PARACELSUS score supportive of PG. The patient was treated with oral prednisolone, cyclosporine, structured wound care, supportive therapy, and physiotherapy, resulting in marked clinical improvement at three-month follow-up. This case demonstrates how structured clinical reasoning and validated diagnostic frameworks can support a clinically well-substantiated diagnosis of probable PG when confirmatory investigations are inaccessible. It also describes a temporal association between disease onset during early pregnancy and pregnancy loss, an observation that should be interpreted cautiously and requires further investigation rather than implying causality. Careful exclusion of alternative causes of ulceration remains fundamental before initiating immunosuppressive therapy.

PMID 42502448
阅读全文 →
PubMedClinics and research in hepatology and gastroenterology2026-07-25

A Comparative Study of Nintedanib versus Conventional Drugs in the Treatment of Inflammatory Bowel Disease-Associated Intestinal Fibrosis.

Wan Meng M, Zhang Lin L, Li Xianghui X, Yang Mi M

Intestinal fibrosis is a severe complication of inflammatory bowel disease (IBD) with limited effective therapeutic interventions. Nintedanib, a multi-target kinase inhibitor, exerts well-characterized antifibrotic activity in pulmonary fibrosis and may serve as a candidate agent for IBD-related intestinal fibrosis. To compare the anti-inflammatory and antifibrotic efficacy of nintedanib with prednisolone and sulfasalazine in a DSS-induced mouse intestinal fibrosis model. Forty-eight C57BL/6 mice were randomly allocated to four DSS-treated intervention groups (12 mice per group: Group A prednisolone, Group B sulfasalazine, Group C nintedanib, Group D normal saline), plus a normal untreated control Group E (n=7). Intestinal fibrosis was induced via four cycles of intermittent 2% DSS drinking water. On Day 26 prior to drug administration, five mice from each group were randomly euthanized for baseline detection to verify successful model establishment. The remaining mice received 14 consecutive days of intragastric treatment. Measured endpoints included body weight recovery, disease activity index (DAI), colon morphological parameters, serum TGF-β and TNF-α levels, and collagen deposition quantified via Masson's trichrome staining. Group C achieved slightly higher body weight recovery (19.6±1.4%) than Group A (18.7±0.2%) and Group B (19.4±1.5%), while Group D only recovered 3.4±0.9% (P<0.001). Nintedanib treatment significantly improved colon length and reduced colon weight compared with the two conventional drugs, though colon length in Group C was still markedly shorter than that of normal mice. Serum TGF-β and TNF-α were reduced more substantially in Group C; however, cytokine concentrations remained 2-3 times higher than baseline values of healthy animals and failed to return to normal levels. Masson staining revealed that collagen deposition in Group C decreased by roughly 10% relative to Groups A and B (25±3.2% vs 35±4.2%, 34±3.8%). Currently, there is no unified gold-standard threshold for evaluating antifibrotic efficacy in preclinical intestinal fibrosis models, and relevant quantitative criteria vary widely across published studies. In this DSS-induced colitis model, nintedanib produced modest anti-inflammatory and collagen-reducing effects compared with prednisolone and sulfasalazine used in this study. These preclinical preliminary results warrant further research to evaluate nintedanib as a potential therapeutic candidate for fibrostenotic Crohn's disease.

PMID 42498025
阅读全文 →
PubMedFrontiers in medicine2026-07-25

Analysis of adverse event reports associated with complementary health products in Singapore from 2017 to 2023.

Quek Yi-Ling YL, Zeng Yun Y, Ge Xiaowei X, Low Min-Yong MY et al.

The use of complementary health products (CHPs), including Chinese Proprietary Medicines (CPMs), health supplements, traditional medicines and homeopathic medicines, has become increasingly prevalent in Singapore's multicultural society. While these products are widely used for maintaining health and treating minor ailments and are generally safe, potential adverse effects have been reported. This study analyzes adverse event reports related to CHPs submitted to Singapore Health Sciences Authority (HSA) from 2017 to 2023. AE reports involving CHPs assessed by the Vigilance and Compliance Branch (VCB) of HSA from 2017 to 2023 were collated and analyzed. The analysis included patient demographics, AE details, suspected product information, medical history, laboratory results, concomitant therapies, and reporter's profession. Of the 182,131 AE reports associated with pharmaceutical products and CHPs, 727 reports (0.4%) were associated with CHPs. Health supplements accounted for the highest number of reports (68% of total). "Skin and appendages disorders" were the most commonly reported system organ class, with glucosamine-containing products accounting for the highest number of adverse events. Patients primarily used CHPs for pain relief (33.1%), general health and wellbeing (20.6%), and weight management (8.8%). Products found to contain undeclared illegal substances were most frequently indicated for pain relief. The three most common adulterants were dexamethasone, chlorpheniramine, and prednisolone. While CHPs are generally safe, adulterated products, especially those from dubious sources, pose real health risks. Healthcare professionals and consumers should remain vigilant about potential adulteration and report suspected CHPs related AEs. Even when causality remains unclear, reporting supports timely regulatory actions when concerning patterns emerge. This study examined 727 adverse event reports associated with CHPs between 2017 and 2023, accounting for 0.4% of all reported adverse events. Health supplements were the most frequently reported category, with glucosamine-containing products accounting for the highest number of adverse events, predominantly affecting the skin. Products found to contain undeclared illegal substances were most frequently indicated for pain relief, with dexamethasone, chlorpheniramine, and prednisolone being the most common adulterants found. These findings highlight the need for continued vigilance in the monitoring of CHPs to safeguard public health.

PMID 42500535
阅读全文 →
PubMedVeterinary medicine and science2026-07-25

Presumptive Postoperative Nontraumatic Adrenal Haemorrhage After Orthopaedic Surgery in a Dog.

Kim Byung-Jun BJ, Cho Hyoung-Sun HS, Song Kun-Ho KH

Nontraumatic adrenal haemorrhage (NTAH) is rarely reported in dogs and may be associated with clinically important adrenal dysfunction when both adrenal glands are affected. Surgery has been recognised as a potential precipitating stressor in humans, but postoperative NTAH has been rarely described in veterinary medicine. A 7-year-old, 2.8-kg spayed female Chihuahua developed abrupt decompensation on postoperative day 1 after bilateral distal femoral osteotomy, characterised by hypothermia, hypotension, and recurrent hypoglycaemia. Clinicopathologic abnormalities included anaemia, thrombocytopenia, hypoalbuminaemia, increased C-reactive protein concentration, and increased D-dimer concentration. Abdominal ultrasonography identified bilateral adrenal enlargement with hypoechoic parenchyma and marked periadrenal hyperechogenicity, supporting a presumptive diagnosis of postoperative NTAH. Prednisolone and supportive care resulted in rapid clinical stabilisation. Basal cortisol, initially within the reference interval, subsequently declined below the assay detection limit (<1.0 µg/dL), accompanied by a decrease in the sodium-to-potassium ratio. Serial ultrasonography documented progressive reductions in adrenal thickness, with the left adrenal thickness decreasing below commonly cited ultrasonographic cutoffs used to support hypoadrenocorticism. Cortisol and electrolyte indices normalised after discontinuation of glucocorticoids. This case highlights presumptive postoperative NTAH as an important differential diagnosis in dogs with abrupt postoperative decompensation and supports the value of serial ultrasonography combined with endocrine and electrolyte monitoring.

PMID 42499308
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone farnesil